Chronic Obstructive Pulmonary Disease (COPD) and emphysema are debilitating conditions that can make even simple tasks like walking or climbing stairs feel insurmountable. For many in the Texas ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that its Zephyr® Valve is now covered by Priority Health® under its ...

Rancho Mirage, CA (April 24, 2019) Eisenhower Health is the first hospital in Southern California to offer a new lung valve treatment for patients with severe COPD/emphysema. Recently approved by the ...

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long ...

The Zephyr valve is a device that can improve breathing in people with emphysema, one of the two most common types of chronic obstructive pulmonary disease (COPD). The valve received approval by the ...

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...

Zephyr Valves are designed for emphysema patients who are often short of breath and doing less of the things they want to do despite regular use of COPD medications and/or oxygen. The tiny, one-way ...

REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ: LUNG) today announced that Health Care Service Corporation (HCSC) has issued a positive coverage policy for the ...